Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: A multicenter phase II study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 2, 2003, Pages 127-131

  Gómez Bernal, Amalia ^a   Cruz, Juan Jesús ^a   García Palomo, Andrés ^b   Arizcun, Alberto ^c   Pujol, Eduardo ^d   Diz, Pilar ^b   Martín, Germán ^a   Fonseca, Emilio ^a   Sánchez, Pedro ^a   Rodríguez, César ^a   Del Barco, Elvira ^a   López, Yolanda ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL DE LEÓN   (Spain)

^c HOSPITAL RÍO CARRIÓN   (Spain)

^d HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

Author keywords

Anthracycline resistant; Biweekly combination; Docetaxel; Metastatic breast cancer; Vinorelbine

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; NAVELBINE;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VISCERAL METASTASIS;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS; VINBLASTINE;

EID: 0344088526     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200304000-00005     Document Type: Article

References (25)

1. Ferlay J, Bray F, Sankila R, et al. EUCAN: cancer incidence, mortality and prevalence in the European Union 1996, version 3.1. IARC CancerBase No. 4. Lyon: IARC Press, 1999.
2. Bergh J, Jonsson PE, Glimelius B, et al. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001;40:253-281.
3. Trudeau ME. Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer. Semin Oncol 1999;26:21-26.
4. Ando M, Watanabe T, Nagata K, et al. Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance. J Clin Oncol 2001;19:336-342.
5. Pivot X, Asmar L, Hortobagyi GN. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer. Int J Oncol 1999;15:381-386.
6. Bruno S, Puerto VL, Mickiewicz E, et al. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol 1995;18:392-396.
7. Fumoleau P, Delozier T, Extra JM, et al. Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience. Semin Oncol 1995;22:22-28.
8. Garcia-Conde J, Lluch A, Martin M, et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994;5:854-857.
9. Ibrahim NK, Rahman Z, Valero V, et al. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 1999;86:1251-1257.
10. Bissery MC, Azti N, Fumoleau P. Docetaxel in combination with vinorelbine: preclinical and clinical correlation. Proc Am Soc Clin Oncol 1996;15:1550.
11. Bissery MC, Vrignaud P, Lavelle F. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. Semin Oncol 1995;22:3-16.
12. Fumoleau P, Fety R, Delecroix V, et al. Docetaxel combined with vinorelbine: phase I results and new study designs. Oncology 1997;11:29-31.
13. Frasci G, Comella P, D'Aiuto G, et al. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study (SICOG). Ann Oncol 2000;11:367-371.
14. Bonfante V, Santoro A, Viviani S, et al. ABVD in the treatment of Hodgkin's disease. Semin Oncol 1992;19:38-44.
15. van der Gaast A, Kok TC, Kerkhofs L, et al. Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer. Br J Cancer 1999;80:1052-1057.
16. Martín C, Isla D, González-Larriba JL, et al. A phase II study of bi-weekly gemcitabine/paclitaxel in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999;18:1781.
17. Udom DI, Vigushin DM, Linardou H, et al. Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. Eur J Cancer 2000;36:177-182.
18. Gelmon KA, O'Reilly SE, Tolcher AW, et al Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996;14:1185-1191.
19. WHO adverse reactions dictionary. Uppsala, Sweden: WHO Collaborating Center for International Drug Monitoring, 1998.
20. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
21. Kornek GV, Ulrich-Pur H, Penz M, et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001;19:621-627.
22. Rodríguez R, Cuevas JM, Machens I, et al. Docetaxel-vinorelbine as second line chemotherapy for advanced breast carcinoma. Breast Cancer Res Treat 1999;57:333.
23. Gralow JR, Ellis GK, Williams MA, et al. Docetaxel plus vinorelbine with concurrent G-CSF support: a phase II study in stage IV breast cancer. Breast Cancer Res Treat 1999;57:347.
24. De Paz L, Lluch A, Martín M, et al. A phase II study of docetaxel (D) and vinorelbine (V) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1999;18:452.
25. Escudero P, Bueso P, Mayordomo JI, et al. Docetaxel + vinorelbine is an active combination for patients with anthracycline-refractory metastatic breast cancer. Results of a phase II trial. Proc Am Soc Clin Oncol 1998;17:529.